Seeking Alpha

Keryx Biopharmaceuticals Inc. (KERX)

()

News & PR
Market Currents

Buzz
Twitter: KERX

Business Intelligence
Transcripts
Events
Key Developments

Analysis - Latest Articles by most recent | most commented

Lihir Gold: A Stellar Options Trade

Dec 3 • Marco Hickey • Comment!
13 Biotechs to Watch for at Hematology Conference

Nov 30 • Michael Becker • Comment!
Still Believe in Antigenics

Nov 24 • VFC's Stock House • 8 Comments
Keryx Biopharmaceuticals' Next Price Movers Will Be Trial News

Oct 27 • VFC's Stock House • 3 Comments
Keryx Biopharma Investors Should Wait for More News on Trials

Oct 9 • VFC's Stock House • 1 Comment
Keryx Pharmaceuticals: Time to Buy Back In

Oct 4 • VFC's Stock House • 1 Comment
Keryx Pharma Could Turn into a Real Winner Down the Road

Sep 30 • VFC's Stock House • 1 Comment
Closing Update for Tuesday, Sept. 29: Dow Fronts Narrow Losses

Sep 29 • Midnight Trader • 1 Comment
Spectrum Pharmaceuticals: Despite Share Offering, Still Cheap vs. Other Cancer Drugmakers

Sep 20 • Justin M. Hall • 3 Comments
Closing Update: Stocks End at Day's Highs, Advance Eight Days Out of Nine

Sep 16 • Midnight Trader • 4 Comments
Biotech Busy with Bevy of Small Deals

Sep 12 • The Burrill Report • 1 Comment
Spectrum Pharma: Post-Zevalin Approval Sales Should Ramp Up

Sep 11 • Justin M. Hall • 23 Comments
Stocks with 10x Gain Since March: Room to Run?

Aug 25 • Dr. Kris • 4 Comments
26 Bullish Breakout Stocks on Big Volume

Aug 4 • Marco Hickey • 3 Comments
Closing Update for Monday, August 3

Aug 3 • Midnight Trader • 2 Comments
FDA Calendar Updates: Transcept Pharma Surges on Deal

Aug 3 • Mike Havrilla • 1 Comment
6 More Stock Briefs

Jun 25 • VFC's Stock House • 9 Comments
FDA Calendar Updates: Keryx Biopharma Announces Phase 2 Results

Jun 9 • Mike Havrilla • 1 Comment
Monday's Closing Update

Jun 8 • Midnight Trader • 8 Comments
Keryx: Another Beneficiary of the ASCO Effect

Jun 3 • Michael Becker • 5 Comments
Klarman, Witmer & Einhorn: Examining 2009 Q1 13F Filings

May 19 • Davy Bui • 2 Comments
SAC Capital Portfolio Update: 37 13G Filings

Jan 15 • Market Folly • Comment!
Best and Worst Performing Stocks in the Russell 3,000 Year to Date

Jun 13, 2008 • Bespoke Investment Group • 2 Comments
Latest Peek Inside the Portfolios of Klarman, Witmer, Third Ave.

May 19, 2008 • Davy Bui • 1 Comment
The Best and Worst Performing Stocks in the U.S.

Apr 24, 2008 • TickerSense • 2 Comments
Sulonex from Keryx: Unlikely Phase III Success

Feb 27, 2008 • Douglas Krohn • 2 Comments
Cancer Stocks: Lagging Again

Jul 16, 2007 • Alan Brochstein • 1 Comment
Cancer Stocks Hammered Once Again

Jun 26, 2007 • Alan Brochstein • 7 Comments
Cancer Stocks Slide Again

Jun 18, 2007 • Alan Brochstein • 1 Comment
Cancer Stocks Plunge Following ASCO Meeting

Jun 11, 2007 • Alan Brochstein • 3 Comments
Cancer Stocks Soar With Annual ASCO Meeting

Jun 4, 2007 • Alan Brochstein • 1 Comment
Cancer Stocks on the Go: Winners and Losers

May 29, 2007 • Alan Brochstein • 3 Comments
Protalix BioTherapeutics: This Dream Could Take Time to Manifest

Apr 13, 2007 • Shlomo Greenberg • 1 Comment
Does Keryx Biopharmaceuticals Deserve Its Valuation?

Oct 19, 2006 • Shlomo Greenberg • Comment!

Keryx Biopharmaceuticals Inc. (KERX)

Analysis - Latest Articles by most recent | most commented

The Seeking Alpha 100

Fastest Climbers

Top Commenters

Top Instabloggers

Top StockTalkers